Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

The board (the "**Board**") of directors (the "**Directors**") of the Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, on 2 November 2023 (after trading hours on 2 November 2023 in Hong Kong), Legend Biotech Corporation ("**Legend Biotech**"), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Selected Market in the United States (the "**U.S.**"), announced that two oral presentations and five poster presentations featuring new and updated data from the CARTITUDE clinical development program evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 65th American Society of Hematology ("**ASH**") Annual Meeting and Exposition taking place in San Diego from 9 December 2023 to 12 December 2023.

For the first time, patient reported outcomes from the Phase 3 CARTITUDE-4 study of cilta-cel versus standard of care treatment in patients with lenalidomide-refractory multiple myeloma after one to three prior lines of therapy will be featured in an oral presentation at ASH. A poster will also present a new analysis of the CARTITUDE-4 study evaluating the efficacy and safety in patients who received cilta-cel as study treatment.

A second oral presentation will include updated efficacy and safety data from Cohorts A and B of the Phase 2 CARTITUDE-2 study evaluating treatment with cilta-cel for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of treatment or with early relapse after first-time treatment.

Oral and poster presentation abstracts from the meeting can be found below.

Abstract Number	**Title**	**Information**
Abstract #1021 Oral Presentation	The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and With Early Relapse After First Line Treatment (Cohort B)	**Session Name:** 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas **Session Date/Time**: 11 December 2023, 4:30PM - 6:00PM PT **Presentation Date/Time**: 11 December 2023, 4:30PM PT

		Location: San Diego Convention Center, Room 6A
Abstract #1063 Oral Presentation	Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Versus Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy	**Session Name:** 905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma **Session Date/Time**: 11 December 2023, 4:30PM - 6:00 PM PT **Presentation Date/Time**: 11 December 2023, 4:30PM PT **Location:** Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4
Abstract #2099 Poster Presentation	Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma From CARTITUDE-1, a Phase 1b/2 Open-label Study, at the ~3 Year Follow-up	**Session Name:** 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I **Session Date/Time**: 9 December 2023, 5:30PM - 7:30PM PT **Location**: San Diego Convention Center, Halls G-H
Abstract #2141 Poster Presentation	Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With 2–4 Prior Lines of Therapy Using A Matching-Adjusted Indirect Comparison	**Session Name**: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I **Session Date/Time**: 9 December 2023, 5:30PM - 7:30PM PT **Location**: San Diego Convention Center, Halls G-H
Abstract #3501 Poster Presentation	Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B and C, and CARTITUDE-4 Studies of Ciltacabtagene Autoleucel (cilta-cel)	**Session Name**: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II **Session Date/Time**: 10 December 2023, 6:00PM - 8:00PM PT **Location**: San Diego Convention Center, Halls G-H
Abstract #4866 Poster Presentation	Efficacy and Safety in Patients With Lenalidomide-Refractory Multiple Myeloma and 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial	**Session Name:** 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III **Session Date/Time**: 11 December 2023, 6:00PM - 8:00PM PT **Location**: San Diego Convention Center, Halls G-H
Abstract #5083 Poster Presentation	Cost per Responder Analysis of Patients With Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-cel From the CARTITUDE-4 Trial	**Session Name:** 902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster III **Session Date/Time:** 11 December 2023, 6:00PM – 8:00PM PT **Location:** San Diego Convention Center, Halls G-H

About CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Ciltacabtagene autoleucel is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B-cells and plasma cells. The cilta-cel CAR protein features two BCMA-targeting single domain antibodies designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.

In December 2017, Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel.

About CARTITUDE-1

CARTITUDE-1 (NCT03548207) is a Phase 1b/2, open-label, single arm, multi-center trial evaluating cilta-cel for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received at least three prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody. The primary objective of the Phase 1b portion of the study was to characterize the safety and confirm the recommended Phase 2 dose of cilta-cel. The Phase 2 portion further evaluated the efficacy of cilta-cel with overall response rate as the primary endpoint.

About CARTITUDE-2

CARTITUDE-2 (NCT04133636) is an ongoing Phase 2 multicohort study evaluating the safety and efficacy of cilta-cel in various clinical settings (Cohorts A, B, C, D, E, F). The primary study objective is to measure the percentage of patients with negative minimal residual disease (MRD).

About CARTITUDE-4

CARTITUDE-4 (NCT04181827) is an ongoing, international, randomized, open-label Phase 3 study evaluating the efficacy and safety of cilta-cel versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, including a PI and an IMiD. The primary endpoint of the study was progression-free survival.

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. In 2023, it is estimated that more than 35,000 people will be diagnosed with multiple myeloma, and more than 12,000 people will die from the disease in the U.S. While some patients with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.

Cautionary Note Regarding Forward-Looking Statements

Statements in this announcement about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech's expectations for CARVYKTI®, such as Legend Biotech's manufacturing and commercialization expectations for CARVYKTI® and the potential effect of treatment with CARVYKTI® and the potential benefits of Legend Biotech's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F filed with the Securities and Exchange Commission on 30 March 2023. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement as anticipated, believed, estimated or expected. Any forward-looking statements contained in this announcement speak only as of the date of this announcement. The Group and Legend Biotech specifically disclaim any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 2 November 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai

* *For identification purposes only*